No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ALLO240621P2500
- 0.30
- +0.17+130.77%
15min DelayClose Jun 18 15:59 ET
0.35High0.27Low
0.30Open0.13Pre Close62 Volume188 Open Interest2.50Strike Price1.86KTurnover0.00%IV1.35%PremiumJun 21, 2024Expiry Date0.27Intrinsic Value100Multiplier2DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma9.91Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $11
Piper Sandler analyst Biren Amin maintains $Allogene Therapeutics(ALLO.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 0.0%
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics(ALLO.US) Director Sells US$26,181.12 in Common Stock
$Allogene Therapeutics(ALLO.US)$ Director Humer Franz B sold 11,200 shares of common stock on May 30, 2024 at an average price of $2.3376 for a total value of $26,181.12.Source: Announcement What is s
Express News | Allogene Therapeutics: Under Share Exchange Agreement, Jv Company Acquired From Overland 100% Equity Interest in Overland Pharmaceuticals (US) Inc
Express News | Allogene Therapeutics Inc: On May 24, Co, Overland Pharmaceuticals, Allogene Overland Biopharm Entered Into a Share Exchange Agreement
Allogene Therapeutics Initiated at Overweight by Piper Sandler
Allogene Therapeutics Initiated at Overweight by Piper Sandler
Comments
$Allogene Therapeutics(ALLO.US$
NEWS
Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $22.000 thousand in sales this quarter. This is a 26.67 percent decrease over sal...
NEWS
Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $22.000 thousand in sales this quarter. This is a 26.67 percent decrease over sal...
$Allogene Therapeutics(ALLO.US$
NEWS
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
NEWS
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
1
$Allogene Therapeutics(ALLO.US$
bottom of the channel, let's see if we can see this getting pumped to 2.50/2.56
bottom of the channel, let's see if we can see this getting pumped to 2.50/2.56
1
Allogene Therapeutics' satisfactory cash runway contrasts with rising cash burn relative to market cap, sparking concerns over future fundraising. Shareholders should closely examine potential future capital raising costs.
$Allogene Therapeutics(ALLO.US$ high potential to sqeeze like a mofo. low float. high short interest. company isnt garbage
Read more